Nilotinib vs. imatinib in Japanese patients with newly diagnosed chronic myeloid leukemia in chronic phase: long-term follow-up of the Japanese ... View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

2017-10-26

AUTHORS

Hirohisa Nakamae, Tetsuya Fukuda, Chiaki Nakaseko, Yoshinobu Kanda, Ken Ohmine, Takaaki Ono, Itaru Matsumura, Akira Matsuda, Makoto Aoki, Kazuo Ito, Hirohiko Shibayama

ABSTRACT

In the ongoing, international, phase 3 study Evaluating Nilotinib Efficacy and Safety in Clinical Trials–Newly Diagnosed Patients (ENESTnd), nilotinib 300 and nilotinib 400 mg, both twice daily, are compared with imatinib 400 mg once daily for the treatment of newly diagnosed chronic myeloid leukemia in the chronic phase (CML-CP). Results for the overall population in ENESTnd (n = 846) showed that nilotinib resulted in higher response rates vs. imatinib and was well tolerated. Outcomes among Japanese patients in ENESTnd were specifically analyzed after 1 year of follow-up, and showed similar trends to the overall population; we present updated analysis of the Japanese subgroup based on 5 years of follow-up. Among Japanese patients in the nilotinib 300-mg (n = 29), nilotinib 400-mg (n = 23), and imatinib (n = 25) arms, 86.2, 78.3, and 60.0%, respectively, achieved major molecular response [BCR-ABL1 ≤ 0.1% on the International Scale (BCR-ABL1IS)] by 5 years, and 65.5, 69.6, and 40.0%, respectively, achieved MR4.5 (BCR-ABL1IS ≤ 0.0032%). Safety results were consistent with prior reports. In this subgroup, one death occurred during treatment in the nilotinib 400-mg twice-daily arm (unknown cause), and one patient in each arm progressed to accelerated phase/blast crisis by the data cutoff. More... »

PAGES

327-336

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/s12185-017-2353-7

DOI

http://dx.doi.org/10.1007/s12185-017-2353-7

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1092351625

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/29076005


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1117", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Public Health and Health Services", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Adult", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Aged, 80 and over", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Antineoplastic Agents", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Asians", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Drug Administration Schedule", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Female", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Follow-Up Studies", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Imatinib Mesylate", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Leukemia, Myelogenous, Chronic, BCR-ABL Positive", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Male", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Middle Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Pyrimidines", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Randomized Controlled Trials as Topic", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Time Factors", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Treatment Outcome", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Young Adult", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Hematology, Osaka City University Hospital, 1-5-7, Asahimachi, Abeno-ku, Osaka-shi, 545-8586, Osaka, Japan", 
          "id": "http://www.grid.ac/institutes/grid.470114.7", 
          "name": [
            "Hematology, Osaka City University Hospital, 1-5-7, Asahimachi, Abeno-ku, Osaka-shi, 545-8586, Osaka, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Nakamae", 
        "givenName": "Hirohisa", 
        "id": "sg:person.01014223462.98", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01014223462.98"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Hematology, Medical Hospital of Tokyo Medical and Dental University, Tokyo, Japan", 
          "id": "http://www.grid.ac/institutes/grid.265073.5", 
          "name": [
            "Department of Hematology, Medical Hospital of Tokyo Medical and Dental University, Tokyo, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Fukuda", 
        "givenName": "Tetsuya", 
        "id": "sg:person.0610272060.01", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0610272060.01"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Hematology, Chiba University Hospital, Chiba, Japan", 
          "id": "http://www.grid.ac/institutes/grid.411321.4", 
          "name": [
            "Department of Hematology, Chiba University Hospital, Chiba, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Nakaseko", 
        "givenName": "Chiaki", 
        "id": "sg:person.01364756342.26", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01364756342.26"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Division of Hematology, Saitama Medical Center Jichi Medical University, Saitama, Japan", 
          "id": "http://www.grid.ac/institutes/grid.410804.9", 
          "name": [
            "Division of Hematology, Saitama Medical Center Jichi Medical University, Saitama, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Kanda", 
        "givenName": "Yoshinobu", 
        "id": "sg:person.0617055140.49", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0617055140.49"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Division of Hematology, Jichi Medical University Hospital, Tochigi, Japan", 
          "id": "http://www.grid.ac/institutes/grid.415016.7", 
          "name": [
            "Division of Hematology, Jichi Medical University Hospital, Tochigi, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Ohmine", 
        "givenName": "Ken", 
        "id": "sg:person.01144457051.28", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01144457051.28"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Oncology Center, Hamamatsu University Hospital, Shizuoka, Japan", 
          "id": "http://www.grid.ac/institutes/grid.471533.7", 
          "name": [
            "Oncology Center, Hamamatsu University Hospital, Shizuoka, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Ono", 
        "givenName": "Takaaki", 
        "id": "sg:person.0754570043.19", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0754570043.19"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Hematology, Kindai University Hospital, Osaka, Japan", 
          "id": "http://www.grid.ac/institutes/grid.413111.7", 
          "name": [
            "Department of Hematology, Kindai University Hospital, Osaka, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Matsumura", 
        "givenName": "Itaru", 
        "id": "sg:person.0760470165.13", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0760470165.13"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Hemato-Oncology, Saitama International Medical Center, Saitama Medical University, Saitama, Japan", 
          "id": "http://www.grid.ac/institutes/grid.412377.4", 
          "name": [
            "Department of Hemato-Oncology, Saitama International Medical Center, Saitama Medical University, Saitama, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Matsuda", 
        "givenName": "Akira", 
        "id": "sg:person.011135527537.13", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.011135527537.13"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Novartis Pharma KK, Tokyo, Japan", 
          "id": "http://www.grid.ac/institutes/grid.418599.8", 
          "name": [
            "Novartis Pharma KK, Tokyo, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Aoki", 
        "givenName": "Makoto", 
        "id": "sg:person.010025131125.50", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.010025131125.50"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Novartis Pharma KK, Tokyo, Japan", 
          "id": "http://www.grid.ac/institutes/grid.418599.8", 
          "name": [
            "Novartis Pharma KK, Tokyo, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Ito", 
        "givenName": "Kazuo", 
        "id": "sg:person.014557151413.42", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.014557151413.42"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Hematology and Oncology, Osaka University Hospital, Osaka, Japan", 
          "id": "http://www.grid.ac/institutes/grid.412398.5", 
          "name": [
            "Department of Hematology and Oncology, Osaka University Hospital, Osaka, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Shibayama", 
        "givenName": "Hirohiko", 
        "id": "sg:person.01273323113.98", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01273323113.98"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1038/leu.2016.5", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1041273297", 
          "https://doi.org/10.1038/leu.2016.5"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s00761-012-2352-5", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1001406977", 
          "https://doi.org/10.1007/s00761-012-2352-5"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/leu.2012.134", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1042361347", 
          "https://doi.org/10.1038/leu.2012.134"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s12185-011-0841-8", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1035334251", 
          "https://doi.org/10.1007/s12185-011-0841-8"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2017-10-26", 
    "datePublishedReg": "2017-10-26", 
    "description": "In the ongoing, international, phase 3 study Evaluating Nilotinib Efficacy and Safety in Clinical Trials\u2013Newly Diagnosed Patients (ENESTnd), nilotinib 300 and nilotinib 400\u00a0mg, both twice daily, are compared with imatinib 400\u00a0mg once daily for the treatment of newly diagnosed chronic myeloid leukemia in the chronic phase (CML-CP). Results for the overall population in ENESTnd (n\u00a0=\u00a0846) showed that nilotinib resulted in higher response rates vs. imatinib and was well tolerated. Outcomes among Japanese patients in ENESTnd were specifically analyzed after 1\u00a0year of follow-up, and showed similar trends to the overall population; we present updated analysis of the Japanese subgroup based on 5\u00a0years of follow-up. Among Japanese patients in the nilotinib 300-mg (n\u00a0=\u00a029), nilotinib 400-mg (n\u00a0=\u00a023), and imatinib (n\u00a0=\u00a025) arms, 86.2, 78.3, and 60.0%, respectively, achieved major molecular response [BCR-ABL1\u00a0\u2264\u00a00.1% on the International Scale (BCR-ABL1IS)] by 5\u00a0years, and 65.5, 69.6, and 40.0%, respectively, achieved MR4.5 (BCR-ABL1IS\u00a0\u2264\u00a00.0032%). Safety results were consistent with prior reports. In this subgroup, one death occurred during treatment in the nilotinib 400-mg twice-daily arm (unknown cause), and one patient in each arm progressed to accelerated phase/blast crisis by the data cutoff.", 
    "genre": "article", 
    "id": "sg:pub.10.1007/s12185-017-2353-7", 
    "isAccessibleForFree": false, 
    "isFundedItemOf": [
      {
        "id": "sg:grant.6141763", 
        "type": "MonetaryGrant"
      }, 
      {
        "id": "sg:grant.7535205", 
        "type": "MonetaryGrant"
      }, 
      {
        "id": "sg:grant.5873713", 
        "type": "MonetaryGrant"
      }, 
      {
        "id": "sg:grant.9340259", 
        "type": "MonetaryGrant"
      }
    ], 
    "isPartOf": [
      {
        "id": "sg:journal.1076985", 
        "issn": [
          "0925-5710", 
          "1865-3774"
        ], 
        "name": "International Journal of Hematology", 
        "publisher": "Springer Nature", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "3", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "107"
      }
    ], 
    "keywords": [
      "chronic myeloid leukemia", 
      "nilotinib 400", 
      "Japanese patients", 
      "nilotinib 300", 
      "chronic phase", 
      "Japanese subgroup", 
      "myeloid leukemia", 
      "accelerated phase/blast crisis", 
      "overall population", 
      "phase 3 study", 
      "major molecular response", 
      "high response rate", 
      "imatinib arm", 
      "daily arm", 
      "ENESTnd trial", 
      "data cutoff", 
      "imatinib 400", 
      "Nilotinib Efficacy", 
      "clinical trials", 
      "safety results", 
      "blast crisis", 
      "patients", 
      "response rate", 
      "prior reports", 
      "ENESTnd", 
      "nilotinib", 
      "imatinib", 
      "leukemia", 
      "subgroups", 
      "trials", 
      "molecular response", 
      "treatment", 
      "arm", 
      "years", 
      "MR4.5", 
      "population", 
      "efficacy", 
      "death", 
      "outcomes", 
      "similar trend", 
      "report", 
      "safety", 
      "cutoff", 
      "response", 
      "study", 
      "rate", 
      "results", 
      "analysis", 
      "trends", 
      "phase", 
      "crisis"
    ], 
    "name": "Nilotinib vs. imatinib in Japanese patients with newly diagnosed chronic myeloid leukemia in chronic phase: long-term follow-up of the Japanese subgroup of the randomized ENESTnd trial", 
    "pagination": "327-336", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1092351625"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/s12185-017-2353-7"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "29076005"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/s12185-017-2353-7", 
      "https://app.dimensions.ai/details/publication/pub.1092351625"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2022-12-01T06:36", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20221201/entities/gbq_results/article/article_749.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.1007/s12185-017-2353-7"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s12185-017-2353-7'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s12185-017-2353-7'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s12185-017-2353-7'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s12185-017-2353-7'


 

This table displays all metadata directly associated to this object as RDF triples.

305 TRIPLES      21 PREDICATES      98 URIs      86 LITERALS      25 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/s12185-017-2353-7 schema:about N2abecee550dc45f59fd43c5d2d86e154
2 N30b2aa8e8ca244cbb48bde06a7b1f9b1
3 N368bd0f98a8c48889c455e31f2d38d89
4 N434461c954474b79985205cc2464d689
5 N6c400fecbccb4925959db03da3c7acdf
6 N6d03eb90abc8474ca352b4234c3a2388
7 N7e1bc5ed7ca840a48c19ad2fdde84b3b
8 N92ad95bf46974e1babd447b6c2949550
9 N97dfaeb3a27e431dad67e86ba93aa0ec
10 N9c60942e04d441169939fdd06fb022ed
11 N9d51bea1c38f41b5ba7d63139eb85b86
12 Nc0e729f51a4942e89d2fb3d0c8951fb5
13 Nc68ab6f0e3f1463fad3f45f44cb2ca56
14 Ncd3e84db49ae46c5ad2e5e2c3cbdb793
15 Ndc1c96b35cc745818ae39633ee0d3ab6
16 Nf553571974cf4c07a827d38c06d68723
17 Nf60421d89dc444048c8d76676f431926
18 Nfe59045ce96547c0806f9637a5c73fb3
19 anzsrc-for:11
20 anzsrc-for:1117
21 schema:author N25d18732a62b43d5b410d1fee9d554cc
22 schema:citation sg:pub.10.1007/s00761-012-2352-5
23 sg:pub.10.1007/s12185-011-0841-8
24 sg:pub.10.1038/leu.2012.134
25 sg:pub.10.1038/leu.2016.5
26 schema:datePublished 2017-10-26
27 schema:datePublishedReg 2017-10-26
28 schema:description In the ongoing, international, phase 3 study Evaluating Nilotinib Efficacy and Safety in Clinical Trials–Newly Diagnosed Patients (ENESTnd), nilotinib 300 and nilotinib 400 mg, both twice daily, are compared with imatinib 400 mg once daily for the treatment of newly diagnosed chronic myeloid leukemia in the chronic phase (CML-CP). Results for the overall population in ENESTnd (n = 846) showed that nilotinib resulted in higher response rates vs. imatinib and was well tolerated. Outcomes among Japanese patients in ENESTnd were specifically analyzed after 1 year of follow-up, and showed similar trends to the overall population; we present updated analysis of the Japanese subgroup based on 5 years of follow-up. Among Japanese patients in the nilotinib 300-mg (n = 29), nilotinib 400-mg (n = 23), and imatinib (n = 25) arms, 86.2, 78.3, and 60.0%, respectively, achieved major molecular response [BCR-ABL1 ≤ 0.1% on the International Scale (BCR-ABL1IS)] by 5 years, and 65.5, 69.6, and 40.0%, respectively, achieved MR4.5 (BCR-ABL1IS ≤ 0.0032%). Safety results were consistent with prior reports. In this subgroup, one death occurred during treatment in the nilotinib 400-mg twice-daily arm (unknown cause), and one patient in each arm progressed to accelerated phase/blast crisis by the data cutoff.
29 schema:genre article
30 schema:isAccessibleForFree false
31 schema:isPartOf N009466dae55140ae9b4c1f65f995a03e
32 N4214bdcc62ba47f5b8df212c74187299
33 sg:journal.1076985
34 schema:keywords ENESTnd
35 ENESTnd trial
36 Japanese patients
37 Japanese subgroup
38 MR4.5
39 Nilotinib Efficacy
40 accelerated phase/blast crisis
41 analysis
42 arm
43 blast crisis
44 chronic myeloid leukemia
45 chronic phase
46 clinical trials
47 crisis
48 cutoff
49 daily arm
50 data cutoff
51 death
52 efficacy
53 high response rate
54 imatinib
55 imatinib 400
56 imatinib arm
57 leukemia
58 major molecular response
59 molecular response
60 myeloid leukemia
61 nilotinib
62 nilotinib 300
63 nilotinib 400
64 outcomes
65 overall population
66 patients
67 phase
68 phase 3 study
69 population
70 prior reports
71 rate
72 report
73 response
74 response rate
75 results
76 safety
77 safety results
78 similar trend
79 study
80 subgroups
81 treatment
82 trends
83 trials
84 years
85 schema:name Nilotinib vs. imatinib in Japanese patients with newly diagnosed chronic myeloid leukemia in chronic phase: long-term follow-up of the Japanese subgroup of the randomized ENESTnd trial
86 schema:pagination 327-336
87 schema:productId N0d3c39906b754da6a33daa8b11280052
88 Nd58492fbf20d497f85ae15538d2c8045
89 Nec3ba7ad8ee0481abee9c46d845e48d6
90 schema:sameAs https://app.dimensions.ai/details/publication/pub.1092351625
91 https://doi.org/10.1007/s12185-017-2353-7
92 schema:sdDatePublished 2022-12-01T06:36
93 schema:sdLicense https://scigraph.springernature.com/explorer/license/
94 schema:sdPublisher N5f7f9850fa374186a156b68b9ef97fc3
95 schema:url https://doi.org/10.1007/s12185-017-2353-7
96 sgo:license sg:explorer/license/
97 sgo:sdDataset articles
98 rdf:type schema:ScholarlyArticle
99 N009466dae55140ae9b4c1f65f995a03e schema:issueNumber 3
100 rdf:type schema:PublicationIssue
101 N0d3c39906b754da6a33daa8b11280052 schema:name doi
102 schema:value 10.1007/s12185-017-2353-7
103 rdf:type schema:PropertyValue
104 N2126d8acab2143d58bc1309b0967ad2a rdf:first sg:person.0760470165.13
105 rdf:rest N22e676050a514888bf387e8d2fbbae20
106 N22e676050a514888bf387e8d2fbbae20 rdf:first sg:person.011135527537.13
107 rdf:rest Nd39a722110ea428cb018be6e05d7c0d9
108 N25d18732a62b43d5b410d1fee9d554cc rdf:first sg:person.01014223462.98
109 rdf:rest N71ab921608b842ec9f203e28c201399f
110 N2abecee550dc45f59fd43c5d2d86e154 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
111 schema:name Leukemia, Myelogenous, Chronic, BCR-ABL Positive
112 rdf:type schema:DefinedTerm
113 N30b2aa8e8ca244cbb48bde06a7b1f9b1 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
114 schema:name Young Adult
115 rdf:type schema:DefinedTerm
116 N368bd0f98a8c48889c455e31f2d38d89 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
117 schema:name Treatment Outcome
118 rdf:type schema:DefinedTerm
119 N38801932cc2b44129b460f182f8efdf2 rdf:first sg:person.014557151413.42
120 rdf:rest N3a627c3de3d1428d94b1b2293bed90ec
121 N3a627c3de3d1428d94b1b2293bed90ec rdf:first sg:person.01273323113.98
122 rdf:rest rdf:nil
123 N4214bdcc62ba47f5b8df212c74187299 schema:volumeNumber 107
124 rdf:type schema:PublicationVolume
125 N434461c954474b79985205cc2464d689 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
126 schema:name Drug Administration Schedule
127 rdf:type schema:DefinedTerm
128 N5f7f9850fa374186a156b68b9ef97fc3 schema:name Springer Nature - SN SciGraph project
129 rdf:type schema:Organization
130 N6c400fecbccb4925959db03da3c7acdf schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
131 schema:name Follow-Up Studies
132 rdf:type schema:DefinedTerm
133 N6d03eb90abc8474ca352b4234c3a2388 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
134 schema:name Middle Aged
135 rdf:type schema:DefinedTerm
136 N71ab921608b842ec9f203e28c201399f rdf:first sg:person.0610272060.01
137 rdf:rest Nb461058fe36b4660a15f20539d6d0789
138 N7e1bc5ed7ca840a48c19ad2fdde84b3b schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
139 schema:name Time Factors
140 rdf:type schema:DefinedTerm
141 N898f06178fe649539f6207621eaed25c rdf:first sg:person.0754570043.19
142 rdf:rest N2126d8acab2143d58bc1309b0967ad2a
143 N92ad95bf46974e1babd447b6c2949550 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
144 schema:name Imatinib Mesylate
145 rdf:type schema:DefinedTerm
146 N97dfaeb3a27e431dad67e86ba93aa0ec schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
147 schema:name Adult
148 rdf:type schema:DefinedTerm
149 N9c60942e04d441169939fdd06fb022ed schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
150 schema:name Aged, 80 and over
151 rdf:type schema:DefinedTerm
152 N9d51bea1c38f41b5ba7d63139eb85b86 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
153 schema:name Pyrimidines
154 rdf:type schema:DefinedTerm
155 Nb461058fe36b4660a15f20539d6d0789 rdf:first sg:person.01364756342.26
156 rdf:rest Nc0c16294431b40e58236c023d1265bd4
157 Nc0c16294431b40e58236c023d1265bd4 rdf:first sg:person.0617055140.49
158 rdf:rest Nd9b45e0ff9aa4a8a968f17d87ed4cb61
159 Nc0e729f51a4942e89d2fb3d0c8951fb5 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
160 schema:name Antineoplastic Agents
161 rdf:type schema:DefinedTerm
162 Nc68ab6f0e3f1463fad3f45f44cb2ca56 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
163 schema:name Female
164 rdf:type schema:DefinedTerm
165 Ncd3e84db49ae46c5ad2e5e2c3cbdb793 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
166 schema:name Asians
167 rdf:type schema:DefinedTerm
168 Nd39a722110ea428cb018be6e05d7c0d9 rdf:first sg:person.010025131125.50
169 rdf:rest N38801932cc2b44129b460f182f8efdf2
170 Nd58492fbf20d497f85ae15538d2c8045 schema:name dimensions_id
171 schema:value pub.1092351625
172 rdf:type schema:PropertyValue
173 Nd9b45e0ff9aa4a8a968f17d87ed4cb61 rdf:first sg:person.01144457051.28
174 rdf:rest N898f06178fe649539f6207621eaed25c
175 Ndc1c96b35cc745818ae39633ee0d3ab6 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
176 schema:name Humans
177 rdf:type schema:DefinedTerm
178 Nec3ba7ad8ee0481abee9c46d845e48d6 schema:name pubmed_id
179 schema:value 29076005
180 rdf:type schema:PropertyValue
181 Nf553571974cf4c07a827d38c06d68723 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
182 schema:name Aged
183 rdf:type schema:DefinedTerm
184 Nf60421d89dc444048c8d76676f431926 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
185 schema:name Randomized Controlled Trials as Topic
186 rdf:type schema:DefinedTerm
187 Nfe59045ce96547c0806f9637a5c73fb3 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
188 schema:name Male
189 rdf:type schema:DefinedTerm
190 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
191 schema:name Medical and Health Sciences
192 rdf:type schema:DefinedTerm
193 anzsrc-for:1117 schema:inDefinedTermSet anzsrc-for:
194 schema:name Public Health and Health Services
195 rdf:type schema:DefinedTerm
196 sg:grant.5873713 http://pending.schema.org/fundedItem sg:pub.10.1007/s12185-017-2353-7
197 rdf:type schema:MonetaryGrant
198 sg:grant.6141763 http://pending.schema.org/fundedItem sg:pub.10.1007/s12185-017-2353-7
199 rdf:type schema:MonetaryGrant
200 sg:grant.7535205 http://pending.schema.org/fundedItem sg:pub.10.1007/s12185-017-2353-7
201 rdf:type schema:MonetaryGrant
202 sg:grant.9340259 http://pending.schema.org/fundedItem sg:pub.10.1007/s12185-017-2353-7
203 rdf:type schema:MonetaryGrant
204 sg:journal.1076985 schema:issn 0925-5710
205 1865-3774
206 schema:name International Journal of Hematology
207 schema:publisher Springer Nature
208 rdf:type schema:Periodical
209 sg:person.010025131125.50 schema:affiliation grid-institutes:grid.418599.8
210 schema:familyName Aoki
211 schema:givenName Makoto
212 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.010025131125.50
213 rdf:type schema:Person
214 sg:person.01014223462.98 schema:affiliation grid-institutes:grid.470114.7
215 schema:familyName Nakamae
216 schema:givenName Hirohisa
217 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01014223462.98
218 rdf:type schema:Person
219 sg:person.011135527537.13 schema:affiliation grid-institutes:grid.412377.4
220 schema:familyName Matsuda
221 schema:givenName Akira
222 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.011135527537.13
223 rdf:type schema:Person
224 sg:person.01144457051.28 schema:affiliation grid-institutes:grid.415016.7
225 schema:familyName Ohmine
226 schema:givenName Ken
227 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01144457051.28
228 rdf:type schema:Person
229 sg:person.01273323113.98 schema:affiliation grid-institutes:grid.412398.5
230 schema:familyName Shibayama
231 schema:givenName Hirohiko
232 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01273323113.98
233 rdf:type schema:Person
234 sg:person.01364756342.26 schema:affiliation grid-institutes:grid.411321.4
235 schema:familyName Nakaseko
236 schema:givenName Chiaki
237 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01364756342.26
238 rdf:type schema:Person
239 sg:person.014557151413.42 schema:affiliation grid-institutes:grid.418599.8
240 schema:familyName Ito
241 schema:givenName Kazuo
242 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.014557151413.42
243 rdf:type schema:Person
244 sg:person.0610272060.01 schema:affiliation grid-institutes:grid.265073.5
245 schema:familyName Fukuda
246 schema:givenName Tetsuya
247 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0610272060.01
248 rdf:type schema:Person
249 sg:person.0617055140.49 schema:affiliation grid-institutes:grid.410804.9
250 schema:familyName Kanda
251 schema:givenName Yoshinobu
252 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0617055140.49
253 rdf:type schema:Person
254 sg:person.0754570043.19 schema:affiliation grid-institutes:grid.471533.7
255 schema:familyName Ono
256 schema:givenName Takaaki
257 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0754570043.19
258 rdf:type schema:Person
259 sg:person.0760470165.13 schema:affiliation grid-institutes:grid.413111.7
260 schema:familyName Matsumura
261 schema:givenName Itaru
262 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0760470165.13
263 rdf:type schema:Person
264 sg:pub.10.1007/s00761-012-2352-5 schema:sameAs https://app.dimensions.ai/details/publication/pub.1001406977
265 https://doi.org/10.1007/s00761-012-2352-5
266 rdf:type schema:CreativeWork
267 sg:pub.10.1007/s12185-011-0841-8 schema:sameAs https://app.dimensions.ai/details/publication/pub.1035334251
268 https://doi.org/10.1007/s12185-011-0841-8
269 rdf:type schema:CreativeWork
270 sg:pub.10.1038/leu.2012.134 schema:sameAs https://app.dimensions.ai/details/publication/pub.1042361347
271 https://doi.org/10.1038/leu.2012.134
272 rdf:type schema:CreativeWork
273 sg:pub.10.1038/leu.2016.5 schema:sameAs https://app.dimensions.ai/details/publication/pub.1041273297
274 https://doi.org/10.1038/leu.2016.5
275 rdf:type schema:CreativeWork
276 grid-institutes:grid.265073.5 schema:alternateName Department of Hematology, Medical Hospital of Tokyo Medical and Dental University, Tokyo, Japan
277 schema:name Department of Hematology, Medical Hospital of Tokyo Medical and Dental University, Tokyo, Japan
278 rdf:type schema:Organization
279 grid-institutes:grid.410804.9 schema:alternateName Division of Hematology, Saitama Medical Center Jichi Medical University, Saitama, Japan
280 schema:name Division of Hematology, Saitama Medical Center Jichi Medical University, Saitama, Japan
281 rdf:type schema:Organization
282 grid-institutes:grid.411321.4 schema:alternateName Department of Hematology, Chiba University Hospital, Chiba, Japan
283 schema:name Department of Hematology, Chiba University Hospital, Chiba, Japan
284 rdf:type schema:Organization
285 grid-institutes:grid.412377.4 schema:alternateName Department of Hemato-Oncology, Saitama International Medical Center, Saitama Medical University, Saitama, Japan
286 schema:name Department of Hemato-Oncology, Saitama International Medical Center, Saitama Medical University, Saitama, Japan
287 rdf:type schema:Organization
288 grid-institutes:grid.412398.5 schema:alternateName Department of Hematology and Oncology, Osaka University Hospital, Osaka, Japan
289 schema:name Department of Hematology and Oncology, Osaka University Hospital, Osaka, Japan
290 rdf:type schema:Organization
291 grid-institutes:grid.413111.7 schema:alternateName Department of Hematology, Kindai University Hospital, Osaka, Japan
292 schema:name Department of Hematology, Kindai University Hospital, Osaka, Japan
293 rdf:type schema:Organization
294 grid-institutes:grid.415016.7 schema:alternateName Division of Hematology, Jichi Medical University Hospital, Tochigi, Japan
295 schema:name Division of Hematology, Jichi Medical University Hospital, Tochigi, Japan
296 rdf:type schema:Organization
297 grid-institutes:grid.418599.8 schema:alternateName Novartis Pharma KK, Tokyo, Japan
298 schema:name Novartis Pharma KK, Tokyo, Japan
299 rdf:type schema:Organization
300 grid-institutes:grid.470114.7 schema:alternateName Hematology, Osaka City University Hospital, 1-5-7, Asahimachi, Abeno-ku, Osaka-shi, 545-8586, Osaka, Japan
301 schema:name Hematology, Osaka City University Hospital, 1-5-7, Asahimachi, Abeno-ku, Osaka-shi, 545-8586, Osaka, Japan
302 rdf:type schema:Organization
303 grid-institutes:grid.471533.7 schema:alternateName Oncology Center, Hamamatsu University Hospital, Shizuoka, Japan
304 schema:name Oncology Center, Hamamatsu University Hospital, Shizuoka, Japan
305 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...